Switzerland-based Roche (SIX: RO, ROG;OTCQX: RHHBY) has received Emergency Use Authorisation from the United States Food and Drug Administration (FDA) for its Elecsys Anti-SARS-CoV-2 S antibody test, it was reported on Tuesday.
The test can be utilised to measure the level of antibodies in people that have been exposed to the SARS-CoV-2 virus. It is aimed at antibodies that are directed against the region of the novel coronavirus known as the spike protein, specifically the area that allows the virus cell to bind to the host cell receptor, that is required for the virus to enter the host cell. It also offers a numerical result from 0.40-250 U/mL and a qualitative result. It runs on the company's widely available cobas e analysers.
The company is to start shipping the Elecsys Anti-SARS-CoV-2 S test to United States laboratories in the next week. The first lab to provide the testing option in the United States is LabCorp, an early adopter of the test with broad geographic reach.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera